Glycomacropeptide Formula With Long Chain Polyunsaturated Fatty Acids And Docosahexaenoic Acid And Low In Phenylalanine
Dietary management of phenylketonuria (PKU) in children from 3 years of age and adults.
Decision on record
- Meeting Nov 2022 Recommended Phenylketonuria
Access path
- Nov 2022Recommended · restricted
vs PKU Sphere20 Powder
- Mar 2026Recommended · restricted
Comparator changed: PKU Sphere20 Powder → PKU Sphere20 (glycomacropeptide formula with…
- PBS listing · Restricted
From the public summary
7.1 The PBAC recommended a General Schedule Restricted Benefit listing of glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine (PKU GMPro Delight®) sachets containing oral powder 40 g for the dietary management of phenylketonuria (PKU) under the same circumstances as glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine (PKU …PSD · Mar 2026
7.2 The PBAC considered that PKU GMPro Delight should be cost-minimised to PKU Sphere20, the comparator accepted by the NPWP at an equivalent price per gram of PE.PSD · Mar 2026
5.12 The submission presented a cost-minimisation approach of PKU Sphere Liquid compared with PKU Sphere20 Powder, based on the same price per gram PE of $0.76 at the approved ex-manufacturer price (AEMP).PSD · Nov 2022
5.13 The proposed AEMP per maximum quantity PE ($1,827.68) is the same as the main comparator PKU Sphere20 Powder. The PBAC considered this to be appropriate as PKU Sphere Liquid contains the same PE as PKU Sphere20 Powder.PSD · Nov 2022
5.5 The submission claimed the nutritional composition of PKU GMPro Delight is therapeutically equivalent to PKU Sphere20 and is expected to deliver comparable clinical outcomes. The submission provided a comparison of the nutritional profile of PKU GMPro Delight with PKU Sphere20 (Table 2).PSD · Mar 2026
5.6 The submission stated one 160 ml serving (40 g powder in 140 ml water) PKU GMPro Delight provides 519 kJ/ 122 kcal, 20 g protein equivalent (PE); 36 mg phenylalanine (PHE), and 100 mg docosahexaenoic acid (DHA).PSD · Mar 2026
5.8 The submission stated PKU Sphere Liquid is less concentrated in PE than PKU Sphere20 Powder. The submission considered patients who switch to PKU Sphere Liquid will require more formulation volume per day of PKU Sphere Liquid to maintain the same level of metabolic control as PKU Sphere20 Powder. The submission considered the extra volume of formulation will not introduce additional calories.PSD · Nov 2022
5.9 The submission stated PKU Sphere Liquid has higher concentration of PE than PKU GMPro LQ and considered patients will require less formulation volume of PKU Sphere Liquid per day to maintain the same level of metabolic control as PKU GMPro LQ. The submission argued PKU Sphere Liquid may improve dietary compliance for patients struggling to consume the large volume. The submission also stated PKU Sphere Liquid contains fewer calories than PKU GMPro LQ.PSD · Nov 2022
Cost-effectiveness
Cost-minimisation submission; no ICER calculated. PBAC recommended cost-minimisation to PKU Sphere20 at equivalent price per gram of protein equivalent, but the requested AEMP for PKU GMPro Delight ($0.825 per gram PE) was higher than PKU Sphere20 ($0.76 per gram PE).
The PBAC considered that PKU GMPro Delight should be cost-minimised to PKU Sphere20, the comparator accepted by the NPWP at an equivalent price per gram of PE. PBAC · 2026
Decision context
PopulationChildren from 3 years of age and adults with phenylketonuria (PKU) requiring dietary management.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Recommended · restricted | PKU Sphere20 (glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in | — | Cost-minimisation |
| Nov 2022 | Recommended · restricted | PKU Sphere20 Powder | — | Cost-minimisation · Cost-minimisation |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to PKU patients requiring glycomacropeptide-based formula; TGA label covers all food for special medical purposes.
Listed in law
PBS listings commencing 1 May 2023 were made by these 5 determinations under the National Health Act 1953. A determination covers every listing that commenced that day, so this is the legal instrument in force for the date — not a document naming this medicine. Open it and check.
| Determination | Made | Status | |
|---|---|---|---|
| PB 34 of 2023 | 27 Apr 2023 | Repealed | PDF ↗ |
| PB 35 of 2023 | 27 Apr 2023 | Repealed | PDF ↗ |
| PB 35 of 2023 | 27 Apr 2023 | Repealed | PDF ↗ |
| PB 36 of 2023 | 27 Apr 2023 | Repealed | PDF ↗ |
| PB 41 of 2023 | 1 May 2023 | Repealed | PDF ↗ |